| Literature DB >> 12533039 |
Anke S Krause1, Martin R Weihrauch, Udo Bode, Gudrun Fleischhack, Thomas Elter, Theodor Heuer, Andreas Engert, Volker Diehl, Andreas Josting.
Abstract
High-dose methotrexate (HDMTX) is a component of many cancer treatment regimens. Despite careful management, delayed renal clearance, followed by extremely high serum levels with potentially life-threatening toxicity can occur. In the present study, we report our results of carboxypeptidase-G2 (CPDG2) rescue in 8 patients with delayed methotrexate elimination and renal impairment after HDMTX therapy for lymphoma or osteosarcoma. A dose of 50 U/kg CPDG2 was administered. MTX plasma levels decreased rapidly and recovery of renal function was observed in all patients. No patient developed severe WHO grade 4 MTX toxicity. CPDG2 provides an alternative route of MTX elimination by converting it to inactive and non-toxic metabolites. CPDG2 rescue was well tolerated, safe and very effective in preventing severe or life-threatening MTX toxicity.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12533039 DOI： 10.1080/1042819021000032953
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022